In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback